Drug Profile
Abivertinib - ACEA Therapeutics
Alternative Names: A 610MA; Abivertinib maleate - ACEA Therapeutics; AC 0100; AC 0100 Maleate; AC-0010MA; ACEA-100610MA; EX-ACEA-0010MA; STI-5656Latest Information Update: 07 Jul 2023
Price :
$50
*
At a glance
- Originator ACEA Biosciences
- Developer ACEA Therapeutics; Guangdong Provincial Peoples Hospital; Hangzhou ACEA Pharmaceutical Research; Sorrento Therapeutics
- Class Acrylamides; Antineoplastics; Antivirals; Fluorobenzenes; Heterocyclic compounds; Piperazines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Apoptosis stimulants; Epidermal growth factor receptor antagonists; Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors; Ras protein inhibitors; Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Marginal zone B-cell lymphoma; Prostate cancer
- Phase I B-cell lymphoma
- No development reported Lung cancer
- Discontinued COVID 2019 infections
Most Recent Events
- 05 Jul 2023 Safety and efficacy data from a phase IIa trial in Marginal zone B-cell lymphoma released by Sorrento Therapeutics
- 05 Jul 2023 Sorrento Therapeutics plans a phase III trial for Marginal zone B-cell lymphoma in China
- 28 Apr 2023 Sorrento Therapeutics suspends the phase II MAVERICK trial in Prostate cancer (Metastatic disease, Combination therapy, Hormone refractory, First-line therapy, Second-line therapy or greater) in USA (PO), due to company filed for chapter 11 bankruptcy (NCT05361915)